¼¼°èÀÇ Áø´Ü¿ë ½ÉÀü°è(ECG) ½ÃÀå
Diagnostic Electrocardiograph (ECG)
»óǰÄÚµå : 1744695
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 296 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,496,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,489,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Áø´Ü¿ë ½ÉÀü°è(ECG) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 78¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 57¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Áø´Ü¿ë ½ÉÀü°è(ECG) ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 5.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 78¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¾ÈÁ¤½Ã ECG ½Ã½ºÅÛÀº CAGR 3.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 20¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ºÆ®·¹½º ECG ½Ã½ºÅÛ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 16¾ï ´Þ·¯, Áß±¹Àº CAGR 8.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Áø´Ü¿ë ½ÉÀü°è(ECG) ½ÃÀåÀº 2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 15¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.6%¿Í 5.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Áø´Ü¿ë ½ÉÀü°è(ECG) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

½ÉÀüµµ Áø´ÜÀÌ ¿À´Ã³¯ ½ÉÇ÷°üÁúȯ °ü¸®ÀÇ Áß½ÉÀÌ µÇ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Áø´Ü¿ë ½ÉÀüµµ(ECG)´Â ¿À·§µ¿¾È ½ÉÇ÷°üÁúȯÀÇ ¹ß°ß, Áø´Ü ¹× ¸ð´ÏÅ͸µÀÇ ±âº» µµ±¸·Î Á¤±â °ËÁø ¹× ÀÀ±Þ »óȲ ¸ðµÎ¿¡¼­ ù ¹øÂ° ¼±Åà °Ë»ç·Î »ç¿ëµÇ¾î ¿Ô½À´Ï´Ù. ½ÉÇ÷°üÁúȯ(CVD)ÀÌ ¿©ÀüÈ÷ Àü ¼¼°è »ç¸Á ¿øÀÎ 1À§ÀÎ »óȲ¿¡¼­ ECG¿Í °°Àº Á¶±â, Á¤È®ÇÏ°í ºñħ½ÀÀûÀÎ Áø´Ü ±â¼úÀÇ Á߿伺Àº ¾Æ¹«¸® °­Á¶Çصµ Áö³ªÄ¡Áö ¾Ê½À´Ï´Ù. ½Ç½Ã°£À¸·Î ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ºü¸¥ ¼Óµµ, »ç¿ë ÆíÀǼº ¹× Áø´Ü ´É·ÂÀ¸·Î ÀÎÇØ º´¿ø, ¿Ü·¡, ÁßȯÀÚ½Ç, ½ÉÁö¾î ÀÏÂ÷ Áø·á¼Ò¿¡¼­µµ ÇʼöÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Áø´Ü¿ë ½ÉÀüµµ´Â ÀÀ±Þóġ ½ÃÀÛ, °í±Þ ¿µ»ó Áø´Ü ¹× ¼ö¼ú ÀÇ·Ú µî Áß¿äÇÑ ÀÇ»ç°áÁ¤¿¡ Áß¿äÇÑ ÁöħÀÌ µË´Ï´Ù. °í·ÉÈ­, ÁÂ½Ä »ýȰ½À°üÀÇ Áõ°¡, °íÇ÷¾Ð, ´ç´¢º´, ºñ¸¸ÀÇ Áõ°¡ µî ½ÉÇ÷°ü À§ÇèÀ» Áõ°¡½ÃŰ´Â ¿äÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÉÀüµµÀÇ ¿ªÇÒÀº Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÉÀüµµ´Â ½ÉÀå °Ç°­ »óŸ¦ È¿À²ÀûÀ¸·Î ¼±º°ÇØ¾ß ÇÏ´Â ¼ö¼ú Àü Æò°¡ ¹× ½ºÆ÷Ã÷ ÀÇÇп¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Àü ¼¼°è °øÁß º¸°Ç ½Ã½ºÅÛÀÌ ¿¹¹æ ÀÇ·á¿¡ ÁßÁ¡À» µÎ°í ÀÖ´Â °¡¿îµ¥, Áø´Ü¿ë ½ÉÀüµµ´Â Áý´Ü °ËÁø ¹× À§Çè °èÃþÈ­¸¦ ÅëÇØ ½ÉÀå ÁúȯÀÇ Á¶±â ¹ß°ß°ú È¿°úÀûÀÎ °ü¸®¸¦ º¸ÀåÇÔÀ¸·Î½á Àå±âÀûÀ¸·Î ÀÇ·á ºñ¿ëÀ» Àý°¨Çϰí ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Áø´Ü¿ë ½ÉÀüµµ ±â±â¿¡ ¾î¶² Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í Àִ°¡?

ÃÖ±Ù ±â¼ú Çõ½ÅÀº Áø´Ü¿ë ½ÉÀüµµ ±â±âÀÇ ±â´É, Á¢±Ù¼º, »ç¿ëÀÚ °æÇè¿¡ Å« º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, º¸´Ù Á¤È®Çϰí È޴뼺ÀÌ ¶Ù¾î³ª¸ç ´õ ±¤¹üÀ§ÇÑ ÇコÄÉ¾î »ýŰ迡 ÅëÇյǰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ 12À¯µµ ½ÉÀüµµ ÀåÄ¡´Â °íÇØ»óµµ ±â·Ï°ú °í±Þ ½ÅÈ£ ÇØ¼®À» ¼öÇàÇÒ ¼ö ÀÖ´Â ¼ÒÇüÀÇ ¹«¼± Áö¿ø AI Áö¿ø µµ±¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ±â°è ÇнÀ ¾Ë°í¸®ÁòÀº ÇöÀç ECG ¼ÒÇÁÆ®¿þ¾î¿¡ ³»ÀåµÇ¾î ÀÓ»óÀǰ¡ ¹Ì¹¦ÇÑ ÀÌ»ó ¡Èĸ¦ °¨ÁöÇϰí, º¸°í¼­ ÀÛ¼ºÀ» ÀÚµ¿È­Çϸç, ÆÇµ¶ÀÚ °£ ÆíÂ÷¸¦ ÁÙÀÏ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ½ºÅ丮Áö¿Í ½Ç½Ã°£ Àü¼ÛÀ» Á¦°øÇÏ´Â ½Ã½ºÅÛµµ ÀÖ¾î ¿ø°ÝÁø·á ¹× ¿ø°Ý ½ÉÀüµµ ¼­ºñ½º°¡ °¡´ÉÇÕ´Ï´Ù. ½º¸¶Æ®¿öÄ¡³ª ÆÐÄ¡¿Í °°Àº ¿þ¾î·¯ºí ½ÉÀüµµ ¸ð´ÏÅ͵µ Áö¼ÓÀûÀÎ ¸®µë ÃßÀû°ú ½É¹æ¼¼µ¿°ú °°Àº ÀϽÃÀûÀÎ ºÎÁ¤¸ÆÀ» °¨ÁöÇÒ ¼ö ÀÖ°ÔÇÔÀ¸·Î½á Ç¥ÁØ ½ÉÀüµµ¿¡¼­´Â ³ªÅ¸³ªÁö ¾Ê´Â ȯÀÚ ¸ð´ÏÅ͸µÀ» À籸ÃàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀüÀÚ ÀÇ·á ±â·Ï(EHR)°úÀÇ ÅëÇÕ ¹× ´Ù¸¥ Áø´Ü ½Ã½ºÅÛ°úÀÇ »óÈ£ ¿î¿ë¼ºÀ» ÅëÇØ ECG µ¥ÀÌÅÍ´Â ÅëÇÕµÈ ¿¬¼ÓÀûÀÎ Ä¡·áÀÇ ÀϺΰ¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¼¾¼­ ±â¼úÀÇ ¹ßÀüÀ¸·Î ¸ð¹ÙÀÏ È¯°æÀ̳ª ¼ÒÀ½ÀÌ ¸¹Àº ȯ°æ¿¡¼­µµ ½ÅÈ£ÀÇ ¼±¸íµµ°¡ Çâ»óµÇ¾î »ç¿ë »ç·Ê¿¡ °ü°è¾øÀÌ ECGÀÇ ½Å·Ú¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ¸·Î Áø´Ü¿ë ½ÉÀüµµÀÇ ¹üÀ§´Â º´¿ø Áß½ÉÀÇ ±â±â¿¡¼­ °³ÀÎÈ­µÈ ¿¹¹æÀû ½ÉÇ÷°ü°è °ü¸®¿¡ ÇʼöÀûÀÎ µµ±¸·Î È®ÀåµÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°è ÀÇ·á ÇöÀå¿¡¼­ Áø´Ü¿ë ½ÉÀüµµ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

½ÉÀå ÁúȯÀÇ ºÎ´ã Áõ°¡, Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ÀÇ·á ½Ã½ºÅÛ Àü¹Ý¿¡ °ÉÃÄ Áø´Ü¿ë ½ÉÀüµµ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °í¼Òµæ ±¹°¡¿¡¼­´Â Àα¸ °í·ÉÈ­¿Í ¸¸¼ºÁúȯÀÇ È®»êÀ¸·Î ÀÎÇØ ÀÏ»óÀûÀÎ Áø·áÀÇ ÀÏȯÀ¸·Î ±âÁØ ½ÉÀüµµ °Ë»ç ¹× ÃßÀû ½ÉÀüµµ °Ë»ç¸¦ Æ÷ÇÔÇÑ ½ÉÀå Æò°¡ÀÇ ºóµµ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â ºñ°¨¿°¼º ÁúȯÀÇ ºÎ´ãÀ» ÁÙÀ̱â À§ÇÑ °øÁߺ¸°Ç ³ë·ÂÀ¸·Î ÀÎÇØ ÀÏÂ÷ Áø·á Áø´Ü¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ECG´Â °¡Àå ºñ¿ë È¿À²ÀûÀÎ µµ±¸ Áß ÇϳªÀÔ´Ï´Ù. ÀÀ±Þ ÀÇ·á ¼­ºñ½º ¹× ±¸±ÞÂ÷¿¡´Â ÈÞ´ë¿ë ½ÉÀüµµ ÀåÄ¡°¡ ÀåÂøµÇ¾î ÀÖ¾î ½ÉÀ帶ºñ ȯÀÚÀÇ ¹® ¾Õ¿¡¼­ºÎÅÍ Ä¡·á±îÁö °É¸®´Â ½Ã°£À» ´ÜÃàÇÏ°í ½ÉÀå µ¥ÀÌÅ͸¦ Áï½Ã º´¿øÀ¸·Î Àü¼ÛÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿Ü·¡ Áø·á¼Ò, ¾à±¹, À̵¿ Áø·á Â÷·®µµ ½Å¼ÓÇÑ À§Çè Æò°¡ ¹× ÀÇ·Ú¸¦ À§ÇØ ECG¸¦ äÅÃÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á º¸Çè»ç ¹× °í¿ëÁÖ´Â Á÷Àå °Ç°­ ÁõÁø ÇÁ·Î±×·¥, Áö¿ª »çȸ È«º¸ ¹× ¿ø°ÝÀÇ·á Ç÷§ÆûÀ» ÅëÇØ ½ÉÇ÷°ü °ËÁøÀ» Àå·ÁÇϰí ÀÖÀ¸¸ç, À̵é Áß »ó´ç¼ö´Â ÇöÀç ECG ±â´ÉÀ» °®Ãß°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±³À° ±â°ü°ú ½ºÆ÷Ã÷ ´Üü°¡ ¿îµ¿¼±¼ö¿Í ÇлýµéÀÇ °©ÀÛ½º·¯¿î ½ÉÀå »ç°í¸¦ ¿¹¹æÇϱâ À§ÇØ ½ÉÀå °ËÁøÀ» Àǹ«È­Çϰí ÀÖ´Â °Íµµ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ȯÀÚµéÀÌ º¸´Ù °³º°ÀûÀ̰í Àû±ØÀûÀÎ °ü¸®¸¦ ¿ä±¸ÇÔ¿¡ µû¶ó, Áø´Ü¿ë ½ÉÀüµµ´Â ÀÓ»ó ¹× ¿¹¹æÀû ÀÇ·á ¼­ºñ½º Á¦°ø ¸ðµ¨ÀÇ º¸ÆíÀûÀÎ ¿ä¼Ò°¡ µÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°è Áø´Ü¿ë ½ÉÀüµµ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Áø´Ü¿ë ½ÉÀüµµ(ECG) ½ÃÀåÀÇ ¼ºÀåÀº ÇコÄÉ¾î ¼ö¿äÀÇ ¼ö·Å, ±â¼ú Çõ½Å, ±ÔÁ¦ Áö¿ø, ¼ÒºñÀÚ ±â´ëÄ¡ÀÇ º¯È­¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ºÎÁ¤¸Æ, ÇãÇ÷¼º ½ÉÁúȯ, ½ÉºÎÀü µî Á¶±â Áø´Ü°ú Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ ½ÉÇ÷°ü°è ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇöÀå Áø´ÜÀÇ º¸±Þ°ú ÇコÄÉ¾î ¼­ºñ½ºÀÇ ºÐ»êÈ­·Î ÀÎÇØ º´¿ø ¿ÜÀÇ È¯°æ¿¡¼­ ECG¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ´Â »õ·Î¿î ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ¿ø°ÝÀÇ·á µµÀÔÀÌ ±ÞÁõÇϸ鼭 °¡»ó Áø·á Ç÷§Æû°ú ÅëÇյǴ ÈÞ´ë¿ë ¿ø°Ý ½ÉÀüµµ ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ Àεµ, Áß±¹, ºê¶óÁú°ú °°ÀÌ Àα¸°¡ ¸¹Àº ±¹°¡¿¡¼­´Â ³óÃÌ ¹× Áö¿ª ±â¹Ý ÀÇ·á ¼­ºñ½º °³¼±À» À§ÇÑ Á¤ºÎÀÇ ³ë·ÂÀ¸·Î ÀÎÇØ ¿ø°ÝÁø·á¼Ò ¹× ¾Æ¿ô¸®Ä¡ ÇÁ·Î±×·¥¿¡ ECG¸¦ µµÀÔÇÏ´Â »ç·Ê°¡ ´Ã°í ÀÖ½À´Ï´Ù. ¹Ì±¹, À¯·´, ¾Æ½Ã¾Æ ÀϺΠÁö¿ª¿¡¼­´Â »óȯ Á¦µµ °³Çõ°ú À¯¸®ÇÑ Á¤Ã¥À¸·Î ÀÎÇØ ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ºñ¿ëÀ» Àý°¨Çϰí ECG¸¦ º¸´Ù ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¾÷°è¿¡¼­´Â Àü ¼¼°è Á¦Á¶¾÷üµéÀÌ Á¶»ç°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, °¡Á¤¿ë ¹× ÀÓ»ó ȯ°æ¿¡ ÀûÇÕÇÑ AI°¡ žÀçµÈ »ç¿ëÇϱ⠽¬¿î ½º¸¶Æ®Æù¿ë ±â±â¸¦ »ý»êÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ½ÉÀüµµÀÇ Áø´Ü ¹üÀ§¸¦ È®´ëÇÏ·Á´Â ÇÏÀÌÅ×Å© ±â¾÷, ½ÉÀ庴 ÇÐȸ, µðÁöÅÐ Çコ ½ºÅ¸Æ®¾÷ °£ÀÇ Çù·Â¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεé·Î ÀÎÇØ ½ÉÀüµµ Áø´Ü Àåºñ ¼¼°è ½ÃÀåÀº °ß°íÇÏ°í ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, ÁøÈ­ÇÏ´Â ½ÉÇ÷°ü Ä¡·á¿¡ ÇʼöÀûÀÎ µµ±¸·Î È®°íÈ÷ ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¾ÈÁ¤½Ã ECG ½Ã½ºÅÛ, ½ºÆ®·¹½º ECG ½Ã½ºÅÛ, ȦÅÍ ¸ð´ÏÅÍ, À̺¥Æ® ¸ð´ÏÅÍ, ¸ð¹ÙÀÏ ½ÉÀå ÅÚ·¹¸ÞÆ®¸® ½Ã½ºÅÛ, ±âŸ Á¦Ç° À¯Çü), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Áø·á¼Ò, ½ÉÀå ¼¾ÅÍ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 44°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¸ÅÃâ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù : Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù : ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м®:

¹Ì±¹ <> Áß±¹ <> ¸ß½ÃÄÚ <> ij³ª´Ù <> EU <> ÀϺ» <> Àεµ <> ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ® : Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Diagnostic Electrocardiograph (ECG) Market to Reach US$7.8 Billion by 2030

The global market for Diagnostic Electrocardiograph (ECG) estimated at US$5.7 Billion in the year 2024, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Resting ECG Systems, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Stress ECG Systems segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.0% CAGR

The Diagnostic Electrocardiograph (ECG) market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Diagnostic Electrocardiograph (ECG) Market - Key Trends & Drivers Summarized

Why Is Diagnostic Electrocardiography Central to Cardiovascular Disease Management Today?

Diagnostic electrocardiography (ECG) has long been a foundational tool in the detection, diagnosis, and monitoring of cardiovascular conditions, serving as a first-line test in both routine checkups and emergency settings. With cardiovascular disease (CVD) remaining the leading cause of mortality worldwide, the importance of early, accurate, and non-invasive diagnostic techniques like ECG cannot be overstated. ECG devices record the electrical activity of the heart and help identify arrhythmias, myocardial infarction, ischemia, and other cardiac anomalies in real time. Their speed, accessibility, and diagnostic power make them indispensable in hospitals, ambulatory settings, intensive care units, and even in primary care clinics. Diagnostic ECGs guide critical decisions-from initiating life-saving interventions to referring patients for advanced imaging or surgery. Their role has only grown with aging populations, increasing sedentary lifestyles, and the global rise in hypertension, diabetes, and obesity-all of which heighten cardiovascular risk. Moreover, ECGs are pivotal in pre-operative evaluations and sports medicine, where cardiac health must be screened efficiently. As public health systems worldwide focus on preventive care, diagnostic ECGs are being adopted more widely for mass screenings and risk stratification, ensuring that heart conditions are detected early and managed effectively, thereby reducing long-term healthcare costs and improving patient outcomes.

How Are Technological Advancements Revolutionizing Diagnostic ECG Devices?

Recent technological innovations are significantly transforming the functionality, accessibility, and user experience of diagnostic ECG devices, making them more accurate, portable, and integrated into broader healthcare ecosystems. Traditional 12-lead ECG machines have evolved into compact, wireless-enabled, and AI-assisted tools capable of performing high-resolution recordings and advanced signal interpretation. Machine learning algorithms are now being embedded into ECG software to assist clinicians in detecting subtle abnormalities, automating report generation, and reducing inter-reader variability. Some systems offer cloud-based storage and real-time transmission, enabling remote consultations and telecardiology services-an especially vital feature in rural and underserved regions. Wearable ECG monitors, such as smartwatches and patches, are also reshaping patient monitoring by allowing for continuous rhythm tracking and detection of transient arrhythmias like atrial fibrillation that might not appear during a standard ECG. Additionally, integration with electronic health records (EHR) and interoperability with other diagnostic systems allow ECG data to become part of a unified care continuum. Advances in sensor technology have enhanced signal clarity even in mobile or high-noise environments, making ECGs more reliable across use cases. These innovations are expanding the scope of diagnostic ECGs from hospital-centric devices to essential tools in personalized and preventive cardiovascular care.

Why Is Demand for Diagnostic ECGs Increasing Across Healthcare Settings Globally?

The demand for diagnostic ECGs is on the rise across healthcare systems globally due to the escalating burden of heart disease, growing awareness of early detection, and expansion of health infrastructure in emerging markets. In high-income countries, aging demographics and widespread chronic disease are driving more frequent cardiac assessments, including baseline and follow-up ECGs as part of routine care. Meanwhile, in low- and middle-income countries, public health initiatives aimed at reducing non-communicable disease burdens are boosting investment in primary care diagnostics, with ECGs being among the most cost-effective tools. Emergency medical services and ambulances are increasingly equipped with portable ECG machines to enable immediate triage and transmission of cardiac data to hospitals, shortening door-to-treatment times for heart attack patients. Outpatient clinics, pharmacies, and mobile health units are also adopting ECGs for rapid risk assessment and referral. Furthermore, health insurers and employers are promoting cardiovascular screenings through workplace wellness programs, community outreach, and telemedicine platforms-many of which now include ECG capabilities. The demand is also fueled by educational institutions and sports organizations conducting mandatory cardiac screening to prevent sudden cardiac events among athletes and students. As access to healthcare expands and patients seek more personalized and proactive management, diagnostic ECGs are becoming a universal component of clinical and preventive healthcare delivery models.

What Are the Key Drivers Accelerating Global Growth in the Diagnostic ECG Market?

The growth in the diagnostic electrocardiograph (ECG) market is propelled by a convergence of healthcare demands, technological innovation, regulatory support, and shifting consumer expectations. Foremost among these is the increasing prevalence of cardiovascular conditions, including arrhythmias, ischemic heart disease, and heart failure, which necessitate early diagnosis and continuous monitoring. The widespread adoption of point-of-care diagnostics and the decentralization of healthcare services have opened new avenues for ECG deployment in non-hospital environments. Additionally, the surge in telehealth adoption, catalyzed by the COVID-19 pandemic, has accelerated the demand for portable and remote ECG devices that integrate with virtual care platforms. Government initiatives aimed at improving rural and community-based healthcare-especially in populous countries like India, China, and Brazil-are further fueling ECG deployment in remote clinics and outreach programs. Reimbursement reforms and favorable policies in the U.S., Europe, and parts of Asia are making ECGs more accessible by reducing patient and provider costs. On the industry side, global manufacturers are investing heavily in R&D to produce AI-powered, user-friendly, and smartphone-compatible devices tailored for home use and clinical environments alike. These efforts are supported by collaborations between tech firms, cardiology associations, and digital health startups, all working to expand ECG’s diagnostic reach. Together, these drivers are shaping a robust and rapidly expanding global market for diagnostic ECG devices, firmly positioning them as indispensable tools in the evolving landscape of cardiovascular care.

SCOPE OF STUDY:

The report analyzes the Diagnostic Electrocardiograph (ECG) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Resting ECG Systems, Stress ECG Systems, Holter Monitors, Event Monitors, Mobile Cardiac Telemetry Systems, Other Product Types); End-Use (Hospitals, Clinics, & Cardiac Centers, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â